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Objectives This study sought to investigate the prevalence, predictors, and outcomes of patients with post-operative ventric-
ular arrhythmia (POVA) in a large cohort of patients.
Background New-onset POVA after cardiac surgery (CS) is uncommon and has controversial prognostic value.
Methods A total of 14,720 consecutive patients undergoing CS at Emory University between January 2004 and July 2010
were included in the study. Data on all-cause mortality were obtained from Social Security Administration death
records. Multivariable regression models were constructed to determine the risk factors for POVA and to esti-
mate the independent impact of POVA on long-term survival after adjusting for 40 different covariates.
Results POVA occurred in 248 patients (1.7%). Patients with POVA were older (63.5 vs. 61.6 years), had lower left ven-
tricular ejection fraction (EF) (43.7 vs. 51.3), and had greater comorbidities (Society of Thoracic Surgeons mor-
tality risk score of 7.2% vs. 3.1%, p  0.001). Multivariable analysis showed that older age (odds ratio [OR]:
1.018 per 1-year increase, p  0.001), emergent surgery (OR: 1.77, p  0.019), and the presence of PVD
(OR: 1.41, p  0.049) were associated with a higher incidence of POVA, whereas higher left ventricular EF
(OR: 0.97 per 1% increase, p  0.001), mild chronic obstructive pulmonary disease (OR: 0.37, p  0.001), and
off-pump surgery (OR: O.41, p  0.001) were associated with a lower incidence of POVA. POVA was associated
with substantially increased adjusted long-term mortality (hazard rate: 2.53, p  0.001) over 3.5 years of follow-up.
Conclusions POVA is associated with increased long-term mortality after CS. Older age, PVD, lower EF, and emergent surgery
are associated with a higher risk of POVA, whereas off-pump surgery seems to be protective. (J Am Coll
Cardiol 2012;60:2664–71) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.08.1011T
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HCoronary artery disease (CAD), structural heart disease, and
left ventricular (LV) dysfunction are among the factors that
predispose to malignant ventricular arrhythmia (VA) (1).
See page 2672
The incidence of VA and its impact on patients with CAD
and LV dysfunction are well described (2–5). Cardiac surgery
(CS) exposes patients with a substrate for VA to various
arrhythmic triggers, such as ischemia, reperfusion injury, he-
modynamic changes, and electrolyte shifts, that could lead to
post-operative VA (POVA). Of note, the reported incidence
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accepted August 30, 2012.of POVA after CS is low, ranging from 0.95% to 3.2% (6–8).
hus, an analysis of POVA and its effect on patient outcomes
equires a large cohort of patients undergoing CS. In this
tudy, we sought to investigate the incidence, predictors, and
utcomes of patients with POVA undergoing CS in a large
ohort of patients.
ethods
tudy protocol. This study was a retrospective cohort
nalysis to look for associations between POVA and long-
erm outcomes. We queried the Society of Thoracic Sur-
eons (STS) Adult Cardiac Database to identify consecutive
atients undergoing CS at Emory University between Jan-
ary 2004 and July 2010. The entire cohort consisted of
4,720 patients. The extracted data included demographic
ariables, pre-existing comorbidities, operation type, and
linical outcomes. The Emory University Institutional Re-
iew Board approved the protocol in compliance with
ealth Insurance Portability and Accountability Act stan-ards and the Declaration of Helsinki. The institutional
(2665JACC Vol. 60, No. 25, 2012 El-Chami et al.
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before obtaining the data on these patients.
The primary study variable was the onset of POVA,
defined as sustained ventricular tachycardia (VT) (lasting
30 s or requiring cardioversion) or ventricular fibrillation
(VF) (242/248 patients met this criteria). The remaining 6
patients had frequent salvos of nonsustained VT that did
not meet the 30-second duration, but the episodes were
frequent, requiring intravenous antiarrhythmic drugs and
transfer to an intensive care unit. POVA, as entered in the
STS database, is defined as VT or VF with no specification
as to which type is present. Thus, the charts of patients with
POVA were reviewed to determine the mechanism of
POVA (VT vs. VF) and the timing of POVA occurrence
(48 vs. 48 h after surgery) when these variables were
available from the medical record. We calculate the primary
endpoint, the survival time after surgery, using the date of
death of patients in the cohort, as identified by the Social
Security Death Index (SSDI), a publicly available national
database of death records extracted from the U.S. Social
Security Administration’s Death Master File Extract. The
SSDI provided the date of death for each patient who died
before the cutoff date of June 30, 2010, allowing computa-
tion of the Kaplan-Meier product-limit estimates and asso-
ciated Cox regressions. Patients alive on this date were
considered censored, and those undergoing operation after
June 30, 2010, were excluded from survival analyses. Be-
cause the SSDI does not list the cause of death, the analysis
describes all-cause long-term mortality.
To help determine the independent impact of POVA on
survival, 40 risk factors of long-term mortality were identi-
fied and harvested from the STS database for use in a
risk-adjusted analysis. Covariates included in the model are
listed in Table 1.
Missing data from the several selected variables included
Caucasian race (n  18, 0.1%), body mass index (n  81,
0.6%), body surface area (n  30, 0.2%), hemoglobin A1C
n  1,765, 12.0%), height (n  29, 0.2%), last creatinine
level (n  61, 0.4%), ejection fraction (EF) (n  1,012,
6.9%), and number of diseased vessels (n  1,200, 8.2%).
Multiple imputation strategies were used in the final regres-
sion models to minimize the selection bias effect inherent in
missing data settings.
Statistical analysis. Bivariate predictors of POVA were
identified using 2-sample t tests and chi-square tests for
numeric and categoric variables, respectively. These statis-
tically significant variables were entered into an associative
logistic regression, allowing the determination of indepen-
dent predictors of POVA. Adjusted odds ratios (ORs) and
95% confidence intervals (CIs) were calculated using this
analysis.
Unadjusted survival estimates were calculated using
Kaplan-Meier product-limit estimation. Kaplan-Meier curves
were generated to compare survival between patients with
and without POVA. Two further stratifications were madein patients with POVA: (a) tim-
ing of POVA ( or 48 h) and
(b) type of POVA (VF or VT,
when available). To statistically
evaluate the independent effect
of POVA on long-term mortal-
ity, a multivariate Cox propor-
tional hazards regression model
was constructed that related sur-
vival time as a function of POVA
while adjusting for 46 collected
covariates to reduce confounding
bias. Adjusted hazard ratios
(AHRs) and 95% CIs were cal-
culated for POVA and the 46
covariates.
All analyses were performed
using SAS version 9.3 (SAS In-
stitute Inc., Cary, North Caro-
lina). No adjustments for multi-
ple tests were performed.
Results
Cohort characteristics. In total,
14,720 patients were included in
the analysis. The majority of pa-
tients were white men with a
mean age of 61.7 years. More
than 80% of the cohort had hy-
pertension, one-third of patients
had diabetes, and 36% of patients
had the diagnosis of congestive
heart failure. A total of 8,863
patients underwent isolated cor-
onary artery bypass grafting (CABG) (60.2%), 3,238 pa-
tients underwent isolated valve surgery (22%), and 1,412
patients underwent combined CABG and valve surgery
(9.6%). Half of all surgeries were performed off-pump
(Table 2). POVA occurred in 248 patients (1.7%). Table 2
shows the characteristics of patients with and without
POVA. Patients with POVA were older (63.5 vs. 61.6
years), had lower mean EF (43.5 % vs. 51.3%), were more
likely to have congestive heart failure (56.9% vs. 35.9%), and
underwent emergent surgery (14.9% vs. 6.4%). The POVA
group had more comorbidities with higher STS mortality
risk score (9) (7.2% vs. 3.1%). Of note, patients with POVA
were less likely to have undergone off-pump coronary artery
bypass (27.0% vs. 50.6%) (Table 2). The mean length of stay
for patients with POVA was double that of patients without
POVA (16.3 vs. 8.03, p  0.001).
Independent predictors of POVA. After identifying the
covariates associated with the occurrence of POVA in
unadjusted bivariate analysis, a multivariable logistic regres-
sion model was performed to determine the independent
Abbreviations
and Acronyms
AHR  adjusted hazard
ratio
CABG  coronary artery
bypass grafting
CAD  coronary artery
disease
CI  confidence interval
COPD  chronic
obstructive pulmonary
disease
CS  cardiac surgery
EF  ejection fraction
HR  hazard ratio
ICD  implantable
cardioverter defibrillator
LV  left ventricular
MI  myocardial infarction
OR  odds ratio
POVA  post-operative
ventricular arrhythmia
PVD  peripheral vascular
disease
SSDI  Social Security
Death Index
STS  Society of Thoracic
Surgeons
VA  ventricular arrhythmia
VF  ventricular fibrillation
VT  ventricular
tachycardiapredictors of POVA (Table 3). Six risk factors were iden-
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age was associated with 19.5% higher risk of POVA with
each 10-year increase in age (OR: 1.019 per 1-year increase
in age). The need for emergent surgery strongly predicted
the occurrence of POVA (OR: 1.77, 95% CI: 1.10 to 2.86).
Higher EF protected against POVA (OR: 0.974, 95% CI:
0.965 to 0.983). Each 10% increase in EF decreased the
odds of POVA by 26%. Off-pump surgery was associated
with a 59% reduction in the odds of POVA compared with
patients undergoing cardiopulmonary bypass (OR: 0.41,
95% CI: 0.30 to 0.55) (Table 3). The presence of peripheral
vascular disease (PVD) predicted the occurrence of POVA,
Covariates Included inthe Associative R gression ModelTable 1 Covariat Include inthe Associative Regression Model
Age BMI (kg/m2)
BSA (m2) Hemoglobin A1C %
Height (cm) Weight (kg)
Pre-operative creatinine No. of prior cardiac surgeries
No. of diseased coronary arteries EF
Chronic lung disease (none, mild,
moderate, or severe)
Race
Female Smoking
Dyslipidemia PVD
Cerebrovascular disease Permanent stroke
Transient ischemic attack Diabetes
Family history of CAD Hypertension
Immunosuppressive therapy Infectious endocarditis
Renal failure Dialysis
Previous CABG Previous valve surgery
Pre-operative VA Congestive heart failure
Index MI Left main disease
Pre-operative intra-aortic pump Cardiopulmonary bypass
Post-operative stroke Post-operative MI
Post-operative AF Post-operative renal failure
Post-operative dialysis Surgical status (elective urgent or emergent)
AF atrial fibrillation; BMI body mass index; BSA body surface area; CABG coronary artery
bypass grafting; CAD coronary artery disease; EF ejection fraction; MImyocardial infarction;
PVD  peripheral vascular disease; VA  ventricular arrhythmia.
Demographic and Clinical Overview of the PatieTable 2 Demographic and Clinical Overview
Characteristic
Overall
(N  14,720)
Age, yr (SD) 61.7 13.3
Mean EF, % 61.7 13.3
Male 9,677 (65.7%)
Caucasian race 10,949 (74.5%)
CABG 10,275 (69.8%)
Emergent surgery 967 (6.6)
Off-pump 7,396 (50.2)
Heart failure 5,342 (36.3%)
Hypertension 11,956 (81.2%)
STS mortality risk score 3.2%
Pre-operative VA 203 (1.4%)
Values are mean  SD or n (%).
CABG  coronary artery bypass grafting (including isolated CABG and CAB
arrhythmia; SD  standard deviation; STS  Society of Thoracic Surgery; VAwhereas the presence of mild chronic obstructive pulmonary
disease (COPD) seemed to be protective (Table 3).
Survival analysis. POVA was associated with increased
long-term mortality over a mean follow-up of 3.5 years.
Patients with POVA had worse long-term survival than
those without POVA, with a high risk of death in the
POVA group during the first 6 postsurgical months
(6-month survival of POVA 59.8% vs. 93.8% for POVA-
ree group). This difference in survival persisted over time
Fig. 1).
After adjusting for the covariates, POVA was indepen-
ently associated with a 153% increase in long-term mor-
ality compared with POVA-free patients (AHR: 2.53, 95%
I: 2.09 to 3.06). To better elucidate the effect of POVA on
ong-term mortality without the confounding effect of
n-hospital mortality and early competing risks, a secondary
nalysis excluded patients who died before hospital dis-
harge. This analysis showed that POVA independently
redicted an increase in long-term mortality with a hazard
atio (HR) of 1.94 (CI: 1.46 to 2.60, p  0.001). Other
ignificant independent prognosticators of long-term sur-
ival (with hospital deaths excluded) are shown in Table 4.
Charts of patients with POVA were reviewed to deter-
mine the mechanism of arrhythmia (VT vs. VF); these data
were missing on 111 patients (45%) with POVA. Among
patients with POVA, VF had a higher early hazard of death
and produced worse long-term survival (unadjusted HR:
1.95, p  0.007) (Fig. 2). POVA occurring 48 h after
surgery demonstrated worse early mortality risk but an
equivalent survival at 6 years compared with POVA occur-
ring within 48 h of surgery (unadjusted HR: 1.16, p 0.31)
(Fig. 3).
The calculated mortality of patients with POVA within
the first year after excluding in-hospital death reached
18.5% (27of 146 patients died within 1 year after hospital
discharge) (Fig. 4). We attempted to identify the charac-
teristics of patients who are at high risk of death in the first
pulatione Patient Population
POVA-Free
(N  14,472)
POVA
(N  248) p Value
61.6 13.3 63.5 13.1 0.031
51.3 13.7 43.5 17.3 0.001
9,519 (65.8) 158 (63.7) 0.50
10,767 (74.5) 182 (73.4) 0.69
10,112 (69.9) 163 (65.7) 0.16
930 (6.4) 37 (14.9) 0.001
7,329 (50.6) 67 (27.0) 0.001
5,201 (35.9) 141 (56.9) 0.001
11,759 (81.3) 197 (79.4) 0.47
3.1% 7.4% 0.001
197 (1.4%) 6 (2.4%) 0.16nt Poof thG  valve); EF  ejection fraction; POVA  post-operative ventricular
 ventricular arrhythmia.
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likely to have a lower EF (39.6% vs. 45.9% p  0.08),
ncreased age (67.9 vs. 62.6 years p  0.044), and an index
I leading to surgery (37.0% vs. 23.5% p  0.15). Because
f the small number of patients, the EF and index MI did not
each statistical significance but did exhibit a strong statistical
rend (p  0.08 and 0.15 for EF and MI, respectively).
Management of patients with POVA. A total of 85
patients (34.3%) with POVA were treated with an antiar-
rhythmic drug (predominantly amiodarone). Twenty pa-
tients (8%) received an implantable cardioverter defibrillator
(ICD) before discharge (a decision guided by an electro-
physiologic study in some patients).
Discussion
This study provides the largest analysis to date of the
incidence, predictors, and outcomes of POVA in patients
Independent Predictors of POVA From a 24-VariRegression Model That Included All Bivariate (UTable 3 Ind pendent Pre ictors of POVA FroRegression Model That Included All
Effect AOR
Low
Confi
Emergent surgery 1.77
Off-pump (no CPB) 0.41
Age of patient* 1.019
EF %* 0.974
PVD 1.41
Mild COPD vs. no COPD 0.37
*Per unit increase in variable level.
AOR  adjusted odds ratio; COPD  chronic obstructive pulmona
peripheral vascular disease.
Figure 1 Kaplan-Meier Survival Curve for Patients With POVA V
Kaplan-Meier survival curve showing that patients with post-operative ventricular aundergoing heart surgery. The 1.7% incidence of POVA in
our population is consistent with that in prior reports (6–8).
Steinberg et al. (6) followed 382 patients undergoing
CABG and found that 12 (3.2%) developed POVA. Two
other reports, one from Canada and one from England,
enrolled 4,784 and 4,411 patients and found the incidence
of POVA was 0.95% and 1.6% (7,8), respectively. The
potentially beneficial effect of myocardial revascularization
might account for the observed low incidence of POVA in
a population with structural heart disease (10,11). Also, the
favorable effect of valve surgery on LV loading conditions
might reduce the proarrhythmic stress and stretch and
associated proarrhythmic risk (12).
Predictors of POVA. The current retrospective analysis
identified 4 factors predisposing to POVA: increased age,
lower EF, the need for emergent surgery, and PVD.
Conversely, we found that off-pump surgery and mild
Associative Logisticted) Predictor of POVA24-Variabl Assoc ative Logistic
riate (Unadjusted) Predictors of POVA
AOR
Bound
Upper 95% AOR
Confidence Bound p Value
2.86 0.019
0.55 0.001
1.030 0.001
0.983 0.001
2.00 0.049
0.66 0.001
se; CPB  cardiopulmonary bypass; EF  ejection fraction; PVD 
s Without POVA
ia (POVA) have worse survival compared with patients without (p  0.001).ablenadjum a
Biva
er 95%
dence
1.10
0.30
1.008
0.965
1.00
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Advanced age repeatedly appears as a risk factor for long-
term mortality after CS (13,14). Two studies looking at risk
of POVA after CS found that patients with POVA are
older than patients without POVA (6,8). Conversely, an-
other study found that age 65 years at the time of surgery
was a risk factor for POVA (7). LV dysfunction, expressed
as a lower EF, also predicted POVA; the mean EF in
patients with POVA in our study was 43.5% versus 51.3%
for the group without POVA. A low EF also strongly
predicted risk for POVA in prior studies that evaluated
predictors of POVA after CS (6–8). The results of ran-
domized clinical trials reinforce the role of EF as a major
risk factor for predicting death in patients with or without
associated coronary disease and myocardial infarction (MI)
(4,5). The need for emergent CABG also strongly predicted
POVA in our patients. Emergency CABG generally carries
a higher risk of in-hospital mortality and added requirements
for hemodynamic support, such as the intra-aortic balloon
pump and intravenous inotropes (15). Patients requiring emer-
gency CABG typically have a higher CAD burden, intractable
ischemia, LV dysfunction, and pre-operative hypotension or
Independent Predictors of Long-Term Survival FrAssociative Cox Proportional Haza ds Model ThTable 4 Ind pendent Predictors of L ng-TerAssociative Cox Proportional Hazar
Effect AHR
POVA 1.94
Age of patient 1.033
Body mass index 1.10
Body surface area 0.043
Smoker 1.34
Dyslipidemia 0.70
Height (in cm) 1.042
PVD 1.34
Cerebrovascular disease 1.28
Mild COPD vs. none 1.23
Severe COPD vs. none 2.10
Diabetes 1.32
Insulin dependence 1.31
Hypertension 1.25
Immunocompromised 1.88
Infectious endocarditis 1.34
Creatinine 1.059
Renal failure 1.69
Dialysis 1.81
Pre-operative history of arrhythmia 1.55
Heart failure 1.31
EF % 0.989
Pre-operative IABP 0.65
Emergent surgery 1.42
Post-operative stroke 1.71
Post-operative new atrial fibrillation 1.19
Post-operative new renal failure 1.53
Post-operative new dialysis 1.91
AHR  adjusted hazard ratio; COPD  chronic obstructive pulmonary
post-operative ventricular arrhythmia; PVD  peripheral vascular diseshock (15), all factors that contribute to the risk of VA. wAscione et al. (7) reported a trend toward a reduction in
POVA with the use of off-pump surgery (47% reduction in
the relative risk, p  0.1) in a center where 23% of CABG
ases were performed off-pump. We observed an association
etween use of an off-pump surgical technique and a 58%
elative reduction in POVA at a center aggressively using
he off-pump approach, with more than 80% of isolated
ABGs performed off-pump. This protective effect of
ff-pump CABG remained significant when using an
ntention-to-treat definition of off-pump CABG (i.e., sur-
eries that start as off-pump and had to be converted to
n-pump are analyzed as off-pump). Avoiding cardiopul-
onary bypass might protect against VA. A long on-pump
ime has been shown to predict POVA (8). The clinical
onsequences of cardiopulmonary bypass include systemic
nflammation, oxidative stress, electrolyte shifts, release of
asoactive substances, and peripheral and cerebral emboli
16). Also, on-pump CABG is associated with a higher
egree of myocardial injury evidenced by increased postsur-
ical troponin and creatinine kinase release (17,18). Isch-
mia, myocardial injury, systemic inflammation, and elec-
rolyte shifts may explain the higher risk of POVA observed
ntained All 40 Covariatesrvival From an
odel That Contained All 40 Covariates
r 95% AHR
dence Bound
Upper 95% AHR
Confidence Bound p Value
1.46 2.60 0.001
1.028 1.039 0.001
1.053 1.149 0.001
0.013 0.146 0.001
1.20 1.50 0.001
0.62 0.79 0.001
1.019 1.065 0.001
1.18 1.53 0.001
1.08 1.51 0.004
1.06 1.43 0.005
1.74 2.54 0.001
1.15 1.52 0.001
1.11 1.55 0.001
1.07 1.47 0.006
1.60 2.23 0.001
1.01 1.77 0.041
1.011 1.109 0.015
1.40 2.05 0.001
1.33 2.46 0.001
1.37 1.76 0.001
1.16 1.48 0.001
0.985 0.993 0.001
0.46 0.91 0.012
1.13 1.79 0.003
1.29 2.27 0.001
1.05 1.35 0.006
1.19 1.96 0.001
1.36 2.67 0.001
e; EF  ejection fraction; IABP  intra-aortic balloon pump; POVA om aat Com Su
ds M
Lowe
Confiith cardiopulmonary bypass.
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heart surgery in women. In the current study, no gender-
based difference in the incidence of POVA after heart
surgery was observed. One possible explanation is that
women in our series had higher rates of off-pump surgery
than men (52.4% vs. 46%, p  0.001), and its protective
effect may have erased a gender-based difference.
Figure 2 Kaplan-Meier Survival Curve for Patients With VT Vers
Kaplan-Meier survival curve showing that patients with ventricular fibrillation (VF) have
Figure 3 Kaplan-Meier Survival Curve by Timing of POVA
Kaplan-Meier survival curve showing that patients with early POVA (48 h) have sThe presence of PVD in this study is found to be
predictive of POVA. PVD is associated with an increased
risk of perioperative morbidity, including the risk of post-
CABG atrial and VA (19,20). It is also an independent
predictor of mortality after CS (21). In addition, PVD is
associated with multiple different comorbidities, such as LV
dysfunction (22), which could predispose to VA. It is
F
survival compared with patients with ventricular tachycardia (VT) (p  0.007).
urvival as patients with late POVA (48 h) (p  0.31).us V
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Ventricular Arrhythmia After Cardiac Surgery December 25, 2012:2664–71conceivable that PVD may signal severity of illness and the
presence of multiple comorbidities that predispose to
POVA.
Patients with moderate and severe COPD are at in-
creased risk of post-CABG mortality (23,24) and morbid-
ity, including hospital length of stay, respiratory infections,
and atrial fibrillation (25,26). In our study, patients with
mild COPD were less likely to have POVA. This may seem
surprising given the association of COPD with worse
outcomes after CABG. However, this association is mainly
seen in patients with moderate or severe COPD, whereas
mild COPD has not been demonstrated to predict worse
outcome after CABG.
POVA and long-term survival. Prior studies have shown
that POVA predicts higher (21.7% to 28.9%) in-hospital
mortality compared with control (1.4% to 1.9%) (7,8). Our
data also show that the in-hospital mortality in patients with
POVA was higher than in those without (31.5% vs. 2.9%,
p  0.001). Ascione et al. (7) noted that the detrimental
ffect of POVA on long-term mortality disappeared after
orrecting for the effect of in-hospital death. We did find
hat the adjusted HR decreased from an AHR of 2.53 (95%
I: 2.09 to 3.06) to an AHR of 1.94 (95% CI: 1.46 to 2.60)
fter excluding patients who died in-hospital; however,
OVA still predicted an increased risk of long-term mor-
ality. This single study analyzed the long-term outcome of
48 patients with POVA. The 3 prior reports analyzed data
rom a combined total of 126 patients with POVA. The
arger number of patients followed in this study may provide
dequate statistical power to detect the effect of POVA on
ong-term mortality.
We should stress that most deaths in patients with
OVA occur in the hospital and within the first year after
ischarge (Fig. 4). The observed 1-year mortality in the
Figure 4 In-Hospital and Yearly Mortality After CS
The incidence of deaths is highest in-hospital (30.5% in the POVA group vs.
2.9% POVA-free group) and in the first year after cardiac surgery (CS) (18.5% in
the POVA group vs. 6% in the POVA-free group). POVA  post-operative ventric-
ular arrhythmia.OVA group exceeded the yearly probability of death seen Pin patients enrolled in the MADIT-II (Multicenter Auto-
matic Defibrillator Implantation trial-II) (4), a group with
LV dysfunction associated with a previous MI. If one
assumes that half of deaths resulted from VT or VF, as is
generally the case in patients with CAD and LV dysfunc-
tion (27), these patients should be screened aggressively to
look for markers of SCD with repeat ambulatory electro-
cardiography monitoring and/or provocative testing. Guide-
lines for an ICD as primary prevention of SCD currently
exclude patients with an EF0.35 and those within 90 days
after undergoing surgical or percutaneous revascularization.
Therefore, aggressive use of ambulatory electrocardiography
monitoring to detect nonsustained VT or induction of VT
during invasive electrophysiologic study would be needed to
identify postsurgical patients who would be indicated to
receive an ICD. Also, more aggressive use of a wearable
defibrillator for a few months after discharge might protect
those at risk during the first year after surgery.
We were able to compare the effect of timing of POVA on
long-term outcome. POVA occurring within 48 h of CS
resulted in similar long-term outcomes as POVA occurring
48 h after CS (p 0.31). The prognostic significance of VA
arly after surgery has been unclear, given that the unstable
lectrical milieu early after cardiopulmonary bypass and reper-
usion may produce transient electrical instability not associ-
ted with chronic risk. Likewise, patients with VA emerging
arly (24 to 48 h) after MI have a better prognosis than
atients with VA late after MI (24 to 48 h) (28). Early-onset
A may result from acute ischemia or reperfusion injury, 2
otentially reversible conditions, and thus early POVA may
ave better outcomes than late POVA. Our data suggest that
he timing of POVA (early vs. late) does not influence
ong-term outcome and challenge the traditional notion that
arly POVA has little if any long-term prognostic value and
hould be ignored after treating the acute episode. This analysis
s limited by the availability of POVA timing data on only 154
f 248 patients (62%).
We also noted that patients with VF after CS have worse
ong-term survival than patients with VT (p  0.007). This
as mainly due to the strong impact of early death seen in
atients with VF, an expected finding because VF results in
mmediate hemodynamic collapse whereas VT may support
erfusion long enough to allow recognition and treatment
efore hemodynamic collapse. The availability of data on VA
echanism (55% of all POVAs) also potentially limits this
nalysis.
tudy limitations. This is a single-center retrospective
tudy analyzing the predictors and outcomes of patients
ith VA after CS, and thus it is subject to the same
ias-based limitations affecting all such retrospective obser-
ational studies. The STS database was not designed to
tudy the effect of POVA on long-term mortality or to
etermine the predictors of POVA. Therefore, the covari-
tes included in the regression models might miss important
actors that might have affected the association between
OVA and long-term mortality. The SSDI reports all-
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December 25, 2012:2664–71 Ventricular Arrhythmia After Cardiac Surgerycause mortality; therefore, data on cardiac and arrhythmic
mortality are lacking. The charts of all patients with POVA
were reviewed to confirm the accurate sustained and malig-
nant nature of these arrhythmias. However, it is conceivable
that some patients with wide complex tachycardia could
have been misdiagnosed with VT, whereas the actual
rhythm is supraventricular arrhythmia with aberrant con-
duction. In addition, some sustained but short episodes of
hemodynamically stable POVA could have been missed.
The bias reduction methods involve the construction of
large models for POVA and long-term mortality that run
the risk of poor estimation of effects via “over-fitting.”
Furthermore, a small amount of missing data existed, and
although sophisticated statistical methods were used to
alleviate bias, the incomplete data collection could still result
in less than optimal inferences. However, the large number
of patients enrolled in this study and the long-term
follow-up do suggest that POVA predicts long-term mor-
tality after CS and that most of the mortality difference is
secondary to a high rate of in-hospital death and within the
first year after surgery in the POVA group.
Conclusions
In this large cohort of patients undergoing CS at Emory
University, we have shown that older age, lower EF, and
emergent surgery predisposes to POVA, whereas off-pump
surgery is found to be protective against its occurrence.
More important, POVA is associated with increased long-
term mortality despite excluding in-hospital death.
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